1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023

Summary

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

GlobalData projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare’s Triumeq (dolutegravir/abacavir/lamivudine), Gilead’s Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Highlights

Key Questions Answered

- How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2013-2023?
- What are the most promising late-stage pipeline drugs in HIV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the unmet needs in HIV treatment management?
- What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Key Findings

- The global HIV therapeutics market was worth approximately $14 billion in 2013, and GlobalData projects this market to reach a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.
- Over GlobalData’s 2013-2023 forecast period, the increased uptake of STRs is expected to drive market growth. KOLs interviewed by GlobalData expect that INI-based STRs - led by ViiV’s Triumeq and Gilead’s Quad 2 - will dominate the marketplace for the duration of the forecast period.
- The most notable barriers of growth over the forecast period include patent expiries of key HIV drugs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan) and compulsory licensing in Brazil and China.

Scope

- Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline HIV market revenue from 2013-2023. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table Of Contents

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023
1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 19
1.2 List of Figures 26
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology 30
3.1.1 Viral Lifecycle 30
3.2 Pathophysiology 33
3.3 Staging and Symptoms 34
3.3.1 Primary or Acute Infection 34
3.3.2 Chronic Infection 35
3.3.3 Advanced Infection/AIDS 35
3.4 Prognosis 37
3.5 Quality of Life 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 41
4.3.1 US 42
4.3.2 5EU 42
4.3.3 Brazil, China, and Japan 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 45
4.4.2 Sources Not Used 55
4.4.3 Forecast Assumptions and Methods 56
4.5 Epidemiological Forecast for HIV in the 8MM (2013-2023) 62
4.5.1 Total Prevalent Cases of HIV 62
4.5.2 Age-Specific Total Prevalent Cases of HIV 64
4.5.3 Sex-Specific Total Prevalent Cases of HIV 66
4.5.4 Age-Standardized Total Prevalence of HIV 68
4.5.5 HIV Cases Treated with ART 69
4.5.6 Cases of HIV in Pregnant Women 70
4.6 Epidemiological Forecast for HIV in Japan (2013-2023) 71
4.6.1 20-Year Diagnosed Prevalent Cases of HIV 71
4.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV 72
4.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV 73
4.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV 74
4.6.5 HIV Cases Treated with ART 75
4.6.6 Cases of HIV in Pregnant Women 76
4.7 Discussion 76
4.7.1 Epidemiological Forecast Insight 76
4.7.2 Limitations of the Analysis 77
4.7.3 Strengths of the Analysis 78
5 Disease Management 79
5.1 Diagnosis and Treatment Overview 79
5.1.1 Screening and Diagnosis 79
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 80
5.1.3 Clinical Practice 82
5.2 US 92
5.2.1 Screening and Diagnosis 94
5.2.2 Clinical Practice 95
5.3 5EU 97
5.3.1 Screening and Diagnosis 98
5.3.2 Clinical Practice 99
5.4 Japan 103
5.4.1 Screening and Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Brazil 107
5.5.1 Screening and Diagnosis 107
5.5.2 Clinical Practice 108
5.6 China 111
5.6.1 Screening and Diagnosis 111
5.6.2 Clinical Practice 112
6 Competitive Assessment 115
6.1 Overview 115
6.2 Product Profiles - Major Brands, Single-Tablet Regimens (STRs) 118
6.2.1 Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) 118
6.2.2 Complera (emtricitabine/TDF/rilpivirine) 124
6.2.3 Stribild (elvitegravir/cobicistat/TDF/emtricitabine) 131
6.2.4 Triumeq (dolutegravir/abacavir/lamivudine) 139
6.3 Product Profiles - Major Brands, Fixed-Dose Combinations 147
6.3.1 Truvada (TDF/emtricitabine) 147
6.3.2 Epzicom (abacavir/lamivudine) 153
6.3.3 Kaletra (lopinavir/ritonavir) 158
6.3.4 Prezcobix (darunavir/cobicistat) 164
6.3.5 Evotaz (atazanavir sulfate/cobicistat) 169
6.4 Product Profiles - Major Brands, Protease Inhibitors 175
6.4.1 Reyataz (atazanavir) 175
6.4.2 Prezista (darunavir) 180
6.5 Product Profiles - Major Brands, Integrase Inhibitors 185
6.5.1 Isentress (raltegravir) 185
6.5.2 Tivicay (dolutegravir) 191
6.5.3 Vitekta (elvitegravir) 199
6.6 Product Profiles - Major Brands, Pharmacokinetic Enhancers 205
6.6.1 Norvir (ritonavir) 205
6.6.2 Tybost (cobicistat) 209
6.7 Other Therapeutic Classes 215
6.7.1 Entry Inhibitors 215
7 Unmet Need and Opportunity 216
7.1 Overview 216
7.2 Therapies with Improved Safety and Tolerability Profiles 218
7.2.1 Unmet Need 218
7.2.2 Gap Analysis 219
7.2.3 Opportunity 220
7.3 Simplified PI-Based ART Regimens with a Reduced Pill Burden 221
7.3.1 Unmet Need 221
7.3.2 Gap Analysis 222
7.3.3 Opportunity 223
7.4 Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV 224
7.4.1 Unmet Need 224
7.4.2 Gap Analysis 225
7.4.3 Opportunity 226
7.5 Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis 226
7.5.1 Unmet Need 226
7.5.2 Gap Analysis 228
7.5.3 Opportunity 228
7.6 Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains 228
7.6.1 Unmet Need 228
7.6.2 Gap Analysis 229
7.6.3 Opportunity 230
7.7 Long-Acting Regimens That Require Less Frequent Administration 230
7.7.1 Unmet Need 230
7.7.2 Gap Analysis 231
7.7.3 Opportunity 232
7.8 Improved Access to Treatment 232
7.8.1 Unmet Need 232
7.8.2 Gap Analysis 233
7.8.3 Opportunity 233
7.9 Progress Towards a Functional Cure 234
7.9.1 Unmet Need 234
7.9.2 Gap Analysis 234
7.9.3 Opportunity 235
8 Pipeline Assessment 236
8.1 Overview 236
8.2 Clinical Trial Mapping 237
8.2.1 Clinical Trials by Country 237
8.3 Promising Drugs in Late-Stage Clinical Development 238
8.3.1 Quad 2 (elvitegravir/cobicistat/emtricitabine/TAF) 241
8.3.2 Darunavir/Cobicistat/Emtricitabine/TAF 252
8.3.3 Emtricitabine/TAF 261
8.3.4 Dutrebis (raltegravir/lamivudine) 269
8.3.5 Doravirine (MK-1439) 276
8.4 Promising Drugs in Early-Stage Clinical Development 284
8.5 Other Drugs in Clinical Development 287
9 Current and Future Players 289
9.1 Overview 289
9.2 Trends in Corporate Strategy 291
9.3 Company Profiles 293
9.3.1 Gilead Sciences 293
9.3.2 ViiV Healthcare 298
9.3.3 AbbVie 303
9.3.4 Merck and Co. 306
9.3.5 Janssen 310
9.3.6 Bristol-Myers Squibb 314
9.3.7 Japan Tobacco 319
9.3.8 Avexa 322
9.3.9 TaiMed Biologics 325
9.3.10 Tobira Therapeutics 327
10 Market Outlook 331
10.1 Global Markets 331
10.1.1 Forecast 331
10.1.2 Drivers and Barriers - Global Issues 337
10.2 United States 339
10.2.1 Forecast 339
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 5EU 348
10.3.1 Forecast 348
10.3.2 Key Events 356
10.3.3 Drivers and Barriers 357
10.4 Japan 363
10.4.1 Forecast 363
10.4.2 Key Events 368
10.4.3 Drivers and Barriers 370
10.5 Brazil 372
10.5.1 Forecast 372
10.5.2 Key Events 377
10.5.3 Drivers and Barriers 378
10.6 China 380
10.6.1 Forecast 380
10.6.2 Key Events 384
10.6.3 Drivers and Barriers 385
11 Appendix 388
11.1 Bibliography 388
11.2 Abbreviations 422
11.3 Methodology 429
11.4 Forecasting Methodology 429
11.4.1 Total Prevalent Cases of HIV 429
11.4.2 20-Year Diagnosed Prevalent Cases of HIV 429
11.4.3 HIV Cases Treated with ART 430
11.4.4 Drugs Included in Each Therapeutic Class 431
11.4.5 Launch and Patent Expiry Dates 432
11.4.6 General Pricing Assumptions 433
11.4.7 Individual Drug Assumptions 435
11.4.8 Generic Erosion 453
11.4.9 Pricing of Pipeline Agents 453
11.5 Primary Research - KOLs Interviewed for This Report 455
11.6 Primary Research - Prescriber Survey 457
11.7 About the Authors 458
11.7.1 Analyst 458
11.7.2 Epidemiologists 458
11.7.3 Therapy Area Director 458
11.7.4 Global Director of Therapy Analysis and Epidemiology 459
11.7.5 Global Head of Healthcare 459
11.8 About GlobalData 460
11.9 Disclaimer 460

1.1 List of Tables
Table 1: Symptoms of HIV-1 Infection and AIDS 36
Table 2: Risk Factors and Comorbidities for HIV 40
Table 3: US, Total Prevalence of HIV in Men and Women (%), Age ?13 Years, 2006-2010 42
Table 4: 5EU, Total Prevalence of HIV in Men (%), All Ages, Selected Years, 2001-2013 42
Table 5: 5EU, Total Prevalence of HIV in Women (%), All Ages, Selected Years, 2001-2013 43
Table 6: 8MM, Sources Used to Forecast theTotal Prevalent Cases of HIV 45
Table 7: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan 46
Table 8: 9MM, Sources Used to Forecast the ART Treatment Rate Among the Total Prevalent Cases of HIV 47
Table 9: 9MM, Sources Used to Forecast the Prevalent Cases of HIV-Positive Pregnant Women 49
Table 10: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023 63
Table 11: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N (Row %), 2013 65
Table 12: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N (Row %), 2013 67
Table 13: 8MM, HIV Cases Treated with ART, N (Col %), All Ages, Both Sexes, Selected Years 2013-2023 70
Table 14: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023 72
Table 15: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N (Row %), 2013 73
Table 16: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013 74
Table 17: Japan, HIV Cases Treated with ART, All Ages, Both Sexes, N, Selected Years 2013-2023 75
Table 18: Treatment Guidelines for HIV-1 Used in the 9MM 81
Table 19: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2013 82
Table 20: Diagnosis and Treatment of HIV Infection, Country Profile - US 93
Table 21: Switching of ART Regimens in the US, 2013 96
Table 22: Diagnosis and Treatment of HIV Infection, Country Profile - 5EU 97
Table 23: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU 100
Table 24: Switching of ART Regimens in the 5EU, 2013 102
Table 25: Diagnosis and Treatment of HIV Infection, Country Profile - Japan 103
Table 26: Switching of ART Regimens in Japan, 2013 106
Table 27: Diagnosis and Treatment of HIV Infection, Country Profile - Brazil 107
Table 28: Switching of ART Regimens in Brazil. 2013 110
Table 29: Diagnosis and Treatment of HIV Infection, Country Profile - China 111
Table 30: Switching of ART Regimens in China, 2013 114
Table 31: Leading Branded Treatments for HIV, 2013 117
Table 32: Product Profile - Atripla 120
Table 33: Antiviral Efficacy of Atripla Compared with Combivir-Efavirenz Combination Therapy 121
Table 34: Atripla's Safety - Adverse Reactions Reported in a 144-Week Clinical Study 122
Table 35: Atripla SWOT Analysis, 2014 123
Table 36: Sales Forecasts ($m) for Atripla, 2013-2023 124
Table 37: Product Profile - Complera 127
Table 38: ECHO and THRIVE Studies of the Complera and Atripla Multi-Tablet Regimens 129
Table 39: Complera SWOT Analysis, 2014 130
Table 40: Sales Forecasts ($m) for Complera, 2013-2023 131
Table 41: Product Profile - Stribild 134
Table 42: Pivotal Phase III Trials of Stribild in Treatment-Na?ve Patients 136
Table 43: Stribild's Adverse Reactions - Pooled Results From the Two Phase III Clinical Trials 137
Table 44: Stribild SWOT Analysis, 2014 138
Table 45: Sales Forecasts ($m) for Stribild, 2013-2023 139
Table 46: Product Profile - Triumeq 143
Table 47: Virologic Efficacy of Triumeq in the Phase III SINGLE Study 144
Table 48: Triumeq's Safety - Adverse Reactions Reported at 96 Weeks in the SINGLE Study 145
Table 49: Triumeq SWOT Analysis, 2014 146
Table 50: Sales Forecasts ($m) for Triumeq, 2013-2023 147
Table 51: Product Profile - Truvada 149
Table 52: Truvada's Efficacy - Results of the SWIFT Trial at 48 Weeks 151
Table 53: Truvada SWOT Analysis, 2014 152
Table 54: Sales Forecasts ($m) for Truvada, 2013-2023 153
Table 55: Product Profile - Epzicom 155
Table 56: Epzicom SWOT Analysis, 2014 157
Table 57: Sales Forecasts ($m) for Epzicom, 2013-2023 158
Table 58: Product Profile - Kaletra 161
Table 59: Kaletra SWOT Analysis, 2014 162
Table 60: Sales Forecasts ($m) for Kaletra, 2013-2023 163
Table 61: Product Profile - Prezcobix 166
Table 62: Efficacy of Prezcobix in the Phase III Trial 167
Table 63: Prezcobix SWOT Analysis, 2014 168
Table 64: Sales Forecasts ($m) for Prezcobix, 2013-2023 169
Table 65: Product Profile - Evotaz 171
Table 66: Efficacy of BMS' Evotaz in the Phase III Study 172
Table 67: Evotaz SWOT Analysis, 2014 174
Table 68: Sales Forecasts ($m) for Evotaz, 2013-2023 175
Table 69: Product Profile - Reyataz 176
Table 70: Reyataz SWOT Analysis, 2014 179
Table 71: Sales Forecasts ($m) for Reyataz, 2013-2023 180
Table 72: Product Profile - Prezista 182
Table 73: Prezista SWOT Analysis, 2014 184
Table 74: Sales Forecasts ($m) for Prezista, 2013-2023 185
Table 75: Product Profile - Isentress 187
Table 76: Percentage of Patients with HIV-1 RNA Levels Table 77: Isentress' Safety - Adverse Reactions Reported in the SMARTMRK Study 189
Table 78: Isentress SWOT Analysis, 2014 189
Table 79: Sales Forecasts ($m) for Isentress, 2013-2023 190
Table 80: Product Profile - Tivicay 192
Table 81: Pivotal Phase III Trials of Tivicay 196
Table 82: Tivicay's Safety - Adverse Reactions Reported in the 48-Week SINGLE Study 197
Table 83: Tivicay SWOT Analysis, 2014 198
Table 84: Sales Forecasts ($m) for Tivicay, 2013-2023 199
Table 85: Product Profile - Vitekta 201
Table 86: Efficacy of Vitekta in the Pivotal Phase III Clinical Study 202
Table 87: Vitekta's Safety - Adverse Reactions Reported in the 96-Week Clinical Study 203
Table 88: Vitekta SWOT Analysis, 2014 204
Table 89: Sales Forecasts ($m) for Vitekta, 2013-2023 205
Table 90: Product Profile - Norvir (ritonavir) 207
Table 91: Norvir SWOT Analysis, 2014 208
Table 92: Sales Forecasts ($m) for Norvir, 2013-2023 209
Table 93: Product Profile - Tybost 211
Table 94: Efficacy of Tybost Versus Ritonavir as a Pharmacoenhancer of Atazanavir in the Phase III Trial 212
Table 95: Tybost SWOT Analysis, 2014 213
Table 96: Sales Forecasts ($m) for Tybost, 2013-2023 214
Table 97: Summary of the Minor Therapeutic Classes of EIs, 2014 215
Table 98: Unmet Need and Opportunity in HIV 217
Table 99: Promising Drugs in Clinical Development for HIV, 2014 238
Table 100: Comparison of Therapeutic Classes in Development for HIV, 2013-2023 241
Table 101: Gilead's Quad 2 - Phase III Clinical Trials 243
Table 102: Product Profile - Quad 2 245
Table 103: Efficacy of Quad 2 and Stribild in Studies 104 and 111 247
Table 104: Adverse Events Associated with Quad 2 vs. Stribild Therapy in two Phase III Clinical Studies 248
Table 105: Renal and Bone Safety of Quad 2 Versus Stribild Treatment in the Two Pivotal Phase III Studies 249
Table 106: Quad 2 SWOT Analysis, 2014 251
Table 107: Sales Forecasts ($m) for Quad 2, 2013-2023 252
Table 108: Product Profile - Darunavir/cobicistat/emtricitabine/TAF 255
Table 109: Efficacy of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study 256
Table 110: Safety of Darunavir/Cobicistat/Emtricitabine/TAF - Adverse Reactions Reported at 48 Weeks in the Phase II Study 257
Table 111: Renal and Bone Safety of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study 258
Table 112: Darunavir/Cobicistat/Emtricitabine/TAF SWOT Analysis, 2014 260
Table 113: Sales Forecasts ($m) for Darunavir/Cobicistat/Emtricitabine/TAF, 2013-2023 261
Table 114: Product Profile - Emtricitabine/TAF 263
Table 115: Two Pivotal Clinical Trials of Emtricitabine/TAF 265
Table 116: Phase III Clinical Trials Assessing the Safety of Emtricitabine/TAF 266
Table 117: Emtricitabine/TAF SWOT Analysis, 2014 268
Table 118: Sales Forecasts ($m) for Emtricitabine/TAF, 2013-2023 269
Table 119: Product Profile - Dutrebis 271
Table 120: Percentage of Patients with HIV-1 RNA Levels of Table 121: Dutrebis SWOT Analysis, 2014 275
Table 122: Sales Forecasts ($m) for Dutrebis, 2013-2023 276
Table 123: Product Profile - Doravirine 278
Table 124: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz 279
Table 125: Doravirine SWOT Analysis, 2014 282
Table 126: Sales Forecasts ($m) for Doravirine, 2013-2023 283
Table 127: Promising Drugs in Early-Stage Clinical Development for HIV, 2014 284
Table 128: Other Earlier-Stage Drugs in Active Clinical Development for HIV, 2014 288
Table 129: Key Companies in the HIV-1 Market in the 9MM, 2014 290
Table 130: Gilead Sciences' HIV Portfolio Assessment, 2014 297
Table 131: Gilead Sciences, SWOT Analysis in HIV, 2013-2023 298
Table 132: ViiV Healthcare's HIV Portfolio Assessment, 2014 302
Table 133: ViiV Healthcare, SWOT Analysis in HIV, 2013-2023 303
Table 134: AbbVie's HIV Portfolio Assessment, 2014 305
Table 135: AbbVie, SWOT Analysis in HIV, 2013-2023 306
Table 136: Merck and Co.'s HIV Portfolio Assessment, 2014 309
Table 137: Merck and Co., SWOT Analysis in HIV, 2013-2023 310
Table 138: Janssen's HIV Portfolio Assessment, 2014 313
Table 139: Janssen, SWOT Analysis in HIV, 2013-2023 314
Table 140: BMS' HIV Portfolio Assessment, 2014 318
Table 141: BMS, SWOT Analysis in HIV, 2013-2023 319
Table 142: Japan Tobacco's HIV Portfolio Assessment, 2014 321
Table 143: Japan Tobacco, SWOT Analysis in HIV, 2013-2023 321
Table 144: Avexa's HIV Portfolio Assessment, 2014 324
Table 145: Avexa, SWOT Analysis in HIV, 2013-2023 324
Table 146: TaiMed Biologics, HIV Portfolio Assessment, 2014 326
Table 147: TaiMed Biologics, SWOT Analysis in HIV, 2013-2023 327
Table 148: Tobira Therapeutics, HIV Portfolio Assessment, 2014 329
Table 149: Tobira Therapeutics, SWOT Analysis in HIV, 2013-2023 330
Table 150: Global Sales Forecasts ($m) for HIV Therapeutics, 2013-2023 333
Table 151: Global HIV Therapeutics Market - Drivers and Barriers, 2013-2023 337
Table 152: Sales Forecasts ($m) for HIV Therapeutics in the US, 2013-2023 342
Table 153: Key Events Impacting Sales of HIV Therapeutics in the US, 2013-2023 345
Table 154: HIV Therapeutics Market in the US - Drivers and Barriers, 2013-2023 346
Table 155: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics, 2013 349
Table 156: Sales Forecasts ($m) for HIV Therapeutics in the 5EU, 2013-2023 352
Table 157: Key Events Impacting Sales of HIV Therapeutics in the 5EU, 2013-2023 356
Table 158: HIV Therapeutics Market in the 5EU - Drivers and Barriers, 2013-2023 357
Table 159: Financing of ART in the 5EU Countries by the National Healthcare Authorities 358
Table 160: Electronic Healthcare Systems Introduced in the 5EU Nations 359
Table 161: ART Initiation Criteria in the 5EU 361
Table 162: Systems Used to Control Drug Prices in the 55EU 362
Table 163: Sales Forecasts ($m) for HIV Therapeutics in Japan, 2013-2023 366
Table 164: Key Events Impacting Sales of HIV Therapeutics in Japan, 2013-2023 369
Table 165: HIV Therapeutics Market in Japan - Drivers and Barriers, 2013-2023 370
Table 166: Sales Forecasts ($m) for HIV Therapeutics in Brazil, 2013-2023 374
Table 167: Key Events Impacting Sales of HIV Therapeutics in Brazil, 2013-2023 377
Table 168: HIV Therapeutics Market in Brazil - Drivers and Barriers, 2013-2023 378
Table 169: Sales Forecasts ($m) for HIV Therapeutics in China, 2013-2023 382
Table 170: Key Events Impacting Sales of HIV Therapeutics in China, 2013-2023 384
Table 171: HIV Therapeutics Market in China - Drivers and Barriers, 2013-2023 385
Table 172: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM 432
Table 173: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM 433
Table 174: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 457

1.2 List of Figures
Figure 1: HIV Lifecycle 31
Figure 2: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023 64
Figure 3: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N, 2013 66
Figure 4: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N, 2013 68
Figure 5: 8MM, Age-Standardized Total Prevalence of HIV, All Ages, N, 2013 69
Figure 6: 8MM, Cases of HIV in Pregnant Women Among the Total Prevalent Cases of HIV in Women, N, 2013 and 2023 71
Figure 7: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023 72
Figure 8: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N, 2013 73
Figure 9: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2013 74
Figure 10: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV, All Ages, N, 2013 75
Figure 11: Japan, Cases of HIV in Pregnant Women Among Diagnosed Prevalent Cases of HIV in Women, N, 2013 and 2023 76
Figure 12: HIV-1 Disease Management Flowchart 92
Figure 13: HIV Therapeutics - Phase II and III Clinical Trials by Country, 2014 237
Figure 14: HIV Phase II/Phase III Pipeline, 2014 239
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2013-2023 240
Figure 16: Potential Clinical and Commercial Positioning of Quad 2 250
Figure 17: Potential Clinical and Commercial Positioning of Darunavir/Cobicistat/Emtricitabine/TAF 259
Figure 18: Potential Clinical and Commercial Positioning of Emtricitabine/TAF 267
Figure 19: Potential Clinical and Commercial Positioning of Dutrebis 274
Figure 20: Potential Clinical and Commercial Positioning of Doravirine 281
Figure 21: Company Portfolio Gap Analysis in HIV, 2013-2023 291
Figure 22: Global Sales for HIV Therapeutics by Country, 2013-2023 335
Figure 23: Global Sales for HIV Therapeutics by Drug Class, 2013-2023 336
Figure 24: Sales for HIV Therapeutics in the US by Drug Class, 2013-2023 344
Figure 25: Sales for HIV Therapeutics in the 5EU by Drug Class, 2013-2023 354
Figure 26: Sales for HIV Therapeutics in the 5EU by Country, 2013-2023 355
Figure 27: Sales for HIV Therapeutics in Japan by Drug Class, 2013-2023 368
Figure 28: Sales for HIV Therapeutics in Brazil by Drug Class, 2013-2023 376
Figure 29: Sales for HIV Therapeutics in China by Drug Class, 2013-2023 383

Companies Mentioned
Gilead Sciences
ViiV Healthcare
AbbVie
Merck and Co.
Janssen
Bristol-Myers Squibb
Japan Tobacco
Avexa
TaiMed Biologics
Tobira Therapeutics

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

Related Market Segments :

Therapy
Anti-Infective

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.